Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30230932 | 0.86 | MAOA (0.48) | MAOACYP2A6 | |
| SCHEMBL900450 | 0.86 | MAOA (0.48) | MAOACYP2A6 | |
| SCHEMBL3185529 | 0.77 | MAOA (0.37) | MAOACYP2A6 | |
| SCHEMBL3185755 | 0.75 | DYRK1A (0.35) | — | |
| Hydrochloric Acid SCHEMBL3186456 | 0.75 | — | — | |
| SCHEMBL4573388 | 0.74 | ALDH1A1 (0.40) | MAOA | |
| SCHEMBL26241631 | 0.72 | MAOA (0.33) | MAOA | |
| SCHEMBL9267934 | 0.70 | MAOA (0.35) | MAOA | |
| SCHEMBL9261093 | 0.70 | ADRA2A (0.33) | MAOA | |
| SCHEMBL9261097 | 0.70 | MAOA (0.40) | MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022779-A1 | Isotopically substituted proton pump inhibitors | NYCOMED GMBH (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20100010047-A1 | Isotopically substituted proton pump inhibitors | TAKEDA GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
| US-7601737-B2 | 2-Pyridinyl)methylsulfinyl]-1H-benzimidazole derivatives; substituents include methoxy and difluoromethoxy; at least one alkyl hydrogen is replaced by a deuterium atom: 5-difluoromethoxy-2-[(3-methoxy-4-monodeuteriomethoxy)-2-pyridinyl)methylsulfinyl]-1H-benzimidazole; gastrointestinal disorders | NYCOMED GMBH (DE) | 2009-10-13 | — | — | US | disclosed |
| US-20080146610-A1 | 2-Pyridinyl)methylsulfinyl]-1H-benzimidazole derivatives; substituents include methoxy and difluoromethoxy; at least one alkyl hydrogen is replaced by a deuterium atom: 5-difluoromethoxy-2-[(3-methoxy-4-monodeuteriomethoxy)-2-pyridinyl)methylsulfinyl]-1H-benzimidazole; gastrointestinal disorders | NYCOMED GMBH (DE) | 2008-06-19 | — | — | US | disclosed |
| EP-1912947-A1 | ISOTOPICALLY SUBSTITUTED PANTOPRAZOLE | Nycomed GmbH (DE) | 2008-04-23 | — | — | EP | disclosed |
| EP-1910293-A1 | ISOTOPICALLY SUBSTITUTED PROTON PUMP INHIBITORS | Nycomed GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007012651-A1 | ISOTOPICALLY SUBSTITUTED PANTOPRAZOLE | NYCOMED GMBH (DE) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007012650-A1 | ISOTOPICALLY SUBSTITUTED PROTON PUMP INHIBITORS | NYCOMED GMBH (DE) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022779-A1 | Isotopically substituted proton pump inhibitors | SLC10A2, ABCB11, SLC10A1 | MAOA 1435/4885CYP2A6 101/4885 |
| US-20080146610-A1 | 2-Pyridinyl)methylsulfinyl]-1H-benzimidazole derivatives; substituents include methoxy and difluoromethoxy; at least one alkyl hydrogen is replaced by a deuterium atom: 5-difluoromethoxy-2-[(3-methoxy-4-monodeuteriomethoxy)-2-pyridinyl)methylsulfinyl]-1H-benzimidazole; gastrointestinal disorders | SLC10A2, CYP2J2, CYP2D6 | MAOA 1499/4885CYP2A6 61/4885 |
| US-20100010047-A1 | Isotopically substituted proton pump inhibitors | SLC10A2, ABCB11, SLC10A1 | MAOA 1435/4885CYP2A6 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.